Fulgent Genetics Stock

Fulgent Genetics Equity

The The Equity of Fulgent Genetics (FLGT) as of Aug 14, 2026 is 1.11 B USD. In the previous year, The Equity was 1.13 B USD — a change of -1.87% (lower).

Equity

1.11 BUSD

YoY

-1.87%

Last updated:

In 2026, Fulgent Genetics's equity was 1.11 B USD, a -1.87% increase from the 1.13 B USD equity in the previous year.

Access this data via the Eulerpool API

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Fulgent Genetics's Equity

Fulgent Genetics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Fulgent Genetics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Fulgent Genetics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Fulgent Genetics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Fulgent Genetics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Fulgent Genetics stock

The Equity of Fulgent Genetics is 1.11 B USD in 2026.

The Equity of Fulgent Genetics changed from 1.13 B USD to 1.11 B USD, representing a -1.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Fulgent Genetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Fulgent Genetics

All Key Metrics — Fulgent Genetics